A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy; Amyloidosis
  • Focus Therapeutic Use
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 22 Nov 2013 New trial record
    • 28 Aug 2013 Results were reported in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top